Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.

被引：0
|
作者：
Liao, Hao
Zhong, Jianxin
Pei, Wendi
Bin, Shao
Liu, Xiao-Ran
Rugo, Hope S.
Li, Huiping
机构：
[1] Peking Univ, Canc Hosp, Beijing, Peoples R China
[2] Peking Univ Third Hosp, Beijing, Peoples R China
[3] Beijing Canc Hosp, Beijing, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[5] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[6] Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[7] Peking Univ Canc Hosp & Inst, Dept Breast Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
535
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant endocrine therapy for resectable breast cancer: A systematic review and meta-analysis.
    Leal, Frederico
    Liutti, Vitor Teixeira
    Santos, Vivian Antunes
    Novis de Figueiredo, Maximiliano Augusto
    Macedo, Ligia Traldi
    Rinck, Jose A.
    Sasse, Andre Deeke
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Toxicity of extended adjuvant aromatase inhibitors therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis.
    Goldvaser, Hadar
    Ribnikar, Domen
    Barnes, Tristan Alexandra
    Cescon, David W.
    Ocana, Alberto
    Amir, Eitan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis (vol 171, pg 535, 2018)
    Wang, Jiayu
    Xu, Binghe
    Wang, Wenna
    Zhai, Xiaoyu
    Chen, Xuelian
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (02) : 487 - 487
  • [44] Endocrine treatment for hormone receptor-positive advanced breast cancer patients with endocrine-sensitive or endocrine-resistant disease: A systematic review and network meta-analysis
    Brandao, M.
    Maurer, C.
    Ziegelmann, P.
    Ponde, N.
    Ferreira, A. R.
    Martel, S.
    Piccart-Gebhart, M.
    Debiasi, M.
    de Azambuja, E.
    Lambertini, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [45] Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials
    Hu, Qiancheng
    Ye, Daoli
    Zhao Xudong
    Wang, Qingfeng
    Gou, Hongfeng
    Luo, Ting
    BMJ OPEN, 2023, 13 (04):
  • [46] Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept
    Hiroji Iwata
    Breast Cancer, 2011, 18 : 92 - 97
  • [47] Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept
    Iwata, Hiroji
    BREAST CANCER, 2011, 18 (02) : 92 - 97
  • [48] Sequential versus concurrent use of chemotherapy and endocrine therapy in the adjuvant treatment of ER-positive breast cancer: A systematic review and Bayesian network meta-analysis.
    Li, Tianfu
    Shan, Zhen
    Yu, Liang
    Kuang, Xiaying
    Zhang, Deyuan
    Lu, Sihong
    Zhang, Qi
    Shao, Nan
    Lin, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial
    Fontein, Duveken B. Y.
    Charehbili, Ayoub
    Nortier, Johan W. R.
    Kranenbarg, Elma Meershoek-Klein
    Kroep, Judith R.
    Putter, H.
    van Riet, Yvonne
    Nieuwenhuijzen, Grard A. P.
    de Valk, Bart
    Terwogt, Jetske M. Meerum
    Algie, Gijs D.
    Liefers, Gerrit-Jan
    Linn, Sabine
    van de Velde, Cornelis J. H.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2190 - 2200
  • [50] The Optimal Duration of Endocrine Therapy in Hormone Receptor-Positive Breast Cancer
    Sledge, George W., Jr.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (06) : 383 - 404
12345